1. Home
  2. ABX vs GYRE Comparison

ABX vs GYRE Comparison

Compare ABX & GYRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Abacus Global Management Inc. Class A Common Stock

ABX

Abacus Global Management Inc. Class A Common Stock

N/A

Current Price

$9.68

Market Cap

725.3M

Sector

Finance

ML Signal

N/A

Logo Gyre Therapeutics Inc.

GYRE

Gyre Therapeutics Inc.

N/A

Current Price

$8.05

Market Cap

759.1M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
ABX
GYRE
Founded
2004
2002
Country
United States
United States
Employees
N/A
N/A
Industry
Investment Managers
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
725.3M
759.1M
IPO Year
N/A
2004

Fundamental Metrics

Financial Performance
Metric
ABX
GYRE
Price
$9.68
$8.05
Analyst Decision
Strong Buy
Analyst Count
0
2
Target Price
N/A
$17.00
AVG Volume (30 Days)
567.7K
88.9K
Earning Date
01-01-0001
01-01-0001
Dividend Yield
2.03%
N/A
EPS Growth
N/A
103.55
EPS
N/A
0.04
Revenue
N/A
$275,000.00
Revenue This Year
$97.36
$11.59
Revenue Next Year
$13.66
$26.31
P/E Ratio
$74.88
$193.78
Revenue Growth
N/A
N/A
52 Week Low
$7.18
$6.11
52 Week High
$10.03
$12.62

Technical Indicators

Market Signals
Indicator
ABX
GYRE
Relative Strength Index (RSI) 66.19 49.33
Support Level $8.10 $7.10
Resistance Level N/A $8.25
Average True Range (ATR) 0.39 0.56
MACD 0.11 -0.07
Stochastic Oscillator 80.45 29.55

Price Performance

Historical Comparison
ABX
GYRE

About ABX Abacus Global Management Inc. Class A Common Stock

Abacus Global Management Inc is a financial services company specializing in alternative asset management, data-driven wealth solutions, technology innovations, and institutional services. The Company organizes its business into five reportable segments Active Management, Originations, Asset Management, Portfolio Servicing, and Technology Services. Its operations are confined to the United States.

About GYRE Gyre Therapeutics Inc.

Gyre Therapeutics Inc is a commercial-stage pharmaceutical company developing and commercializing small-molecule anti-inflammatory and anti-fibrotic drugs targeting organ diseases, focusing specifically on organ fibrosis. The company's commercial-stage products include ETUARY, Avatrombopag, and Nintedanib. In addition, it is focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis (MASH fibrosis). Gyre is also advancing a diverse pipeline of different drug candidates in China, including F573, F528, and F230. The company's reportable segments are Gyre Pharmaceuticals, which derives maximum revenue from the sale of ETUARY and certain generic drugs in the PRC, Gyre, and Other.

Share on Social Networks: